M5 and M6 Cytokeratin 18 Monoclonal Antibodies (K18) Research Use Only Cat. No. #10600-10650
M5 / M6 Keratin 18 (Cytokeratin 18) monoclonal antibodies (FFPE-grade) (Prod. No. 10600-10650)
In eukaryotic cells, the cytoskeleton is composed of three different types of morphologically distinct filamentous structures:
- microfilaments,
- intermediate filaments (IF)
- microtubules.
The epithelial keratins (IF types I and II, also called cytokeratins) are conserved phylogenetically and are closely related, biochemically and immunologically. Keratins 1-8 constitute the type II group (53-68 kDa, neutral to basic protein components), while keratins 9-20 constitute the type I group (40-56 kDa, acidic proteins).
Upon release from dying cells, keratins provide useful markers for epithelial malignancies, distinctly reflecting ongoing cellular turnover. Certain keratins, the most prominent example being keratin 18, are substrates for lethal caspase activation and the subsequent release of defined protein fragments occurs during apoptotic cell death.
The clinical value of determining different soluble keratin protein fragments in blood samples (i.e. using the M30 Apoptosense® ELISA or M65® ELISA) lies in the rapid and non-invasive assessment of drug efficacy or response to therapy in epithelial cell carcinomas.
Download Product Resources
Instructions of Use (CE-IVD)
Manuals (RUO)
Material Safety Data Sheets
Brand | PEVIVA |
Code | 10600 |
Instructions of Use (CE-IVD)
COVID-19 Antigen Rapid Test
M30 Apoptosense® ELISA
M65® ELISA
M65 EpiDeath® ELISA
M65 EpiRatTM ELISA
Manuals (RUO)
M30 CytoDeath™ ELISA
M30 CytoDEATH™ MAb
M30 CytoDEATH™ FITC MAb
M30 CytoDEATH™ BIOTIN MAb
M30 CytoDEATH™ Orange MAb
M6 Keratin 18 MAb
M5 Keratin 18 MAb
Material Safety Data Sheets
M30 Apoptosense ELISA MSDS
M65® ELISA MSDS
M65 EpiDeath® ELISA MSDS
M30 CytoDeath™ ELISA MSDS
M30 CytoDEATH™ MAb MSDS
M30 CytoDEATH™ FITC MAb MSDS
M30 CytoDEATH™ BIOTIN MAb MSDS
M30 CytoDEATH™ Orange MAb MSDS
M6 Keratin 18 MAb MSDS
M5 Keratin 18 MAb MSDS
Other Documents
COVID-19 Antigen Rapid Test Declaration of Conformity
COVID-19 Antigen Rapid Test Clinical Study Protocol